242 related articles for article (PubMed ID: 8214004)
1. Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome.
Medeiros LJ; Gelb AB; Wolfson K; Doggett R; McGregor B; Cox RS; Horning SJ; Warnke RA
Am J Pathol; 1993 Oct; 143(4):1086-97. PubMed ID: 8214004
[TBL] [Abstract][Full Text] [Related]
2. HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.
Jesionek-Kupnicka D; Bojo M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Jabłońska J; Kalinka-Warzocha E; Kordek R; Młynarski W; Robak T; Warzocha K; Lech-Maranda E
Arch Immunol Ther Exp (Warsz); 2016 Jun; 64(3):225-40. PubMed ID: 26667793
[TBL] [Abstract][Full Text] [Related]
3. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.
Möller P; Momburg F; Koretz K; Moldenhauer G; Herfarth C; Otto HF; Hämmerling GJ; Schlag P
Cancer Res; 1991 Jan; 51(2):729-36. PubMed ID: 1985791
[TBL] [Abstract][Full Text] [Related]
4. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
[TBL] [Abstract][Full Text] [Related]
5. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.
List AF; Spier CM; Miller TP; Grogan TM
Leukemia; 1993 Mar; 7(3):398-403. PubMed ID: 7680400
[TBL] [Abstract][Full Text] [Related]
6. MHC antigen expression in human oral squamous carcinoma cell lines.
Mutlu S; Matthews JB; Midda M; Scully C; Prime SS
J Pathol; 1991 Oct; 165(2):129-36. PubMed ID: 1744799
[TBL] [Abstract][Full Text] [Related]
7. Class I and class II major histocompatibility complex antigens expression on human hepatocytes and hepatoma cells: an approach with high sensitivity and specificity.
Chiu JH; Lui WY; Chang HM; Loong CC; Wu LH; Kao HL; Wu CW
Cytometry; 1997 Dec; 30(6):317-23. PubMed ID: 9440824
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.
Rybski JA; Spier CM; Miller TP; Lippman SM; McGee DL; Grogan TM
Leuk Lymphoma; 1991; 6(1):31-8. PubMed ID: 27457573
[TBL] [Abstract][Full Text] [Related]
9. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer.
Jo YS; Lee JC; Li S; Choi YS; Bai YS; Kim YJ; Lee IS; Rha SY; Ro HK; Kim JM; Shong M
Int J Cancer; 2008 Feb; 122(4):785-90. PubMed ID: 17957790
[TBL] [Abstract][Full Text] [Related]
10. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
Rimsza LM; Roberts RA; Miller TP; Unger JM; LeBlanc M; Braziel RM; Weisenberger DD; Chan WC; Muller-Hermelink HK; Jaffe ES; Gascoyne RD; Campo E; Fuchs DA; Spier CM; Fisher RI; Delabie J; Rosenwald A; Staudt LM; Grogan TM
Blood; 2004 Jun; 103(11):4251-8. PubMed ID: 14976040
[TBL] [Abstract][Full Text] [Related]
11. HLA class II antigen expression in human papillomavirus-associated cervical cancer.
Glew SS; Duggan-Keen M; Cabrera T; Stern PL
Cancer Res; 1992 Jul; 52(14):4009-16. PubMed ID: 1377602
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma.
Booman M; Douwes J; Glas AM; Riemersma SA; Jordanova ES; Kok K; Rosenwald A; de Jong D; Schuuring E; Kluin PM
Clin Cancer Res; 2006 May; 12(9):2698-705. PubMed ID: 16675561
[TBL] [Abstract][Full Text] [Related]
13. Regulation of major histocompatibility gene expression in human vascular smooth muscle cells.
Warner SJ; Friedman GB; Libby P
Arteriosclerosis; 1989; 9(3):279-88. PubMed ID: 2470342
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
15. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.
Riemersma SA; Jordanova ES; Schop RF; Philippo K; Looijenga LH; Schuuring E; Kluin PM
Blood; 2000 Nov; 96(10):3569-77. PubMed ID: 11071656
[TBL] [Abstract][Full Text] [Related]
16. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
[TBL] [Abstract][Full Text] [Related]
17. Transplantation of canine malignant lymphomas in the nude and SCID mouse.
Baron T; Doré JF
In Vivo; 1992; 6(1):77-9. PubMed ID: 1627746
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
Bijen CB; Bantema-Joppe EJ; de Jong RA; Leffers N; Mourits MJ; Eggink HF; van der Zee AG; Hollema H; de Bock GH; Nijman HW
Int J Cancer; 2010 Mar; 126(6):1417-27. PubMed ID: 19728333
[TBL] [Abstract][Full Text] [Related]
19. Major histocompatibility complex (MHC)-I and MHC-II expression in Hodgkin's disease in relation to the presence of Epstein-Barr Virus (EBV).
Tzardi M; Kouvidou C; Papakonstantinou E; Datseris G; Darivianaki K; Karidi E; Eliopoulos G; Delidis G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(2):827-31. PubMed ID: 8687136
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
